The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-04 and is reviewed periodically as new material appears.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
, the denominator of the logarithm. Thus, the logarithm in the equation results in a positive entry if the alignment is more likely due to point accepted mutations, and a negative entry if the alignment is more likely due to chance.
Strategic Cyber Security, ISBN 978-9949-9040-7-5, 169 pages Halpern, Sue, "The Drums of Cyberwar" (review of Andy Greenberg, Sandworm: A New Era of Cyberwar and the Hunt for the Kremlin's Most Dangerous Hackers, Doubleday, 2019, 348 pp.), The New York Review of Books, vol. LXVI, no. 20 (19 December 2019), pp. 14, 16, 20. Harris, Shane (2014). @War: The Rise of the Military-Internet Complex. Eamon Dolan/Houghton Mifflin Harcourt. ISBN 978-0-544-25179-3. Hunt, Edward (2012). "US Government Computer Penetration Programs and the Implications for Cyberwar". IEEE Annals of the History of Computing. 34 (3): 4–21. Bibcode:2012IAHC...34c...4H. doi:10.1109/mahc.2011.82. S2CID 16367311. Kestner, Peter (2024). The Art of Cyber Warfare: Strategic and Tactical Approaches for Attack and Defense in the Digital Age (1st ed.). Wiesbaden: Springer. pp. XX, 292. doi:10.1007/978-3-658-43879-1. ISBN 978-3-658-43879-1. Janczewski, Lech; Colarik, Andrew M. (2007). Cyber Warfare and Cyber Terrorism. Idea Group Inc (IGI). ISBN 978-1-59140-992-2. Rid, Thomas (2012). "Cyber War Will Not Take Place". Journal of Strategic Studies. 35 (1): 5–32. doi:10.1080/01402390.2011.608939. S2CID 153828543. Springer, Paul J. (2025). Encyclopedia of Cyber Warfare (2nd ed.). New York: Bloomsbury Academic. p. 464. ISBN 9781440881619. Woltag, Johann-Christoph: 'Cyber Warfare' in Rüdiger Wolfrum (Ed.) Max Planck Encyclopedia of Public International Law (Oxford University Press 2012).
== Modes of delivery == There are three general categories of DNA construct delivery: physical, chemical, and viral. Physical methods, which deliver the DNA by physically penetrating the cell, include microinjection, electroporation, and biolistics. Chemical methods rely on chemical reactions to deliver the DNA and include transformation with cells made competent using calcium phosphate as well as delivery via lipid nanoparticles. Viral methods use a variety of viral vectors to deliver the DNA, including adenovirus, lentivirus, and herpes simplex virus
=== Reactions === Crisis services for the LGBTQ+ community saw a sharp increase in usage during the election week. The Trevor Project's crisis lines saw a 125% increase since around midnight on election night according to a statement by CEO Jaymes Black on November 6, and followed an about 200% increase in election related conversations that had been seen November 3–4. By November 8, it was reported that the organization saw an overall increase by 700%. The Crisis Text Line also reported that 56% of their users reported as LGBTQ+ on election day. A company that assists wealthy Americans in securing foreign citizenship saw a 200× jump in inquiries following the election.
=== EC 1.13.11 With incorporation of two atoms of oxygen === EC 1.13.11.1: catechol 1,2-dioxygenase EC 1.13.11.2: catechol 2,3-dioxygenase EC 1.13.11.3: protocatechuate 3,4-dioxygenase EC 1.13.11.4: gentisate 1,2-dioxygenase EC 1.13.11.5: homogentisate 1,2-dioxygenase EC 1.13.11.6: 3-hydroxyanthranilate 3,4-dioxygenase EC 1.13.11.7: deleted EC 1.13.11.8: protocatechuate 4,5-dioxygenase EC 1.13.11.9: 2,5-dihydroxypyridine 5,6-dioxygenase EC 1.13.11.10: 7,8-dihydroxykynurenate 8,8a-dioxygenase EC 1.13.11.11: tryptophan 2,3-dioxygenase EC 1.13.11.12: linoleate 13S-lipoxygenas EC 1.13.11.13: The activity is the sum of several enzymatic and spontaneous reactions EC 1.13.11.14: 2,3-dihydroxybenzoate 3,4-dioxygenase EC 1.13.11.15: 3,4-dihydroxyphenylacetate 2,3-dioxygenase EC 1.13.11.16: 3-carboxyethylcatechol 2,3-dioxygenase EC 1.13.11.17: indole 2,3-dioxygenase EC 1.13.11.18: persulfide dioxygenase EC 1.13.11.19: cysteamine dioxygenase EC 1.13.11.20: cysteine dioxygenase EC 1.13.11.21: Now EC 1.14.99.36, β-carotene 15,15′-monooxygenase EC 1.13.11.22: caffeate 3,4-dioxygenase EC 1.13.11.23: 2,3-dihydroxyindole 2,3-dioxygenase EC 1.13.11.24: quercetin 2,3-dioxygenase EC 1.13.11.25: 3,4-dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 4,5-dioxygenase EC 1.13.11.26: peptide-tryptophan 2,3-dioxygenase EC 1.13.11.27: 4-hydroxyphenylpyruvate dioxygenase EC 1.13.11.28: 2,3-dihydroxybenzoate 2,3-dioxygenase EC 1.13.11.29: stizolobate synthase EC 1.13.11.30: stizolobinate synthase EC 1.13.11.31: arachidonate 12-lipoxygenase EC 1.13.11.32: Now EC 1.13.12.16, nitronate monooxygenase EC 1.13.11.33: arachidonate 15-lipoxygenase EC 1.13.11.34: arachidonate 5-lipoxygenase EC 1.13.11.35: pyrogallol 1,2-oxygenase EC 1.13.11.36: chloridazon-catechol dioxygenase EC 1.13.11.37: hydroxyquinol 1,2-dioxygenase EC 1.13.11.38: 1-hydroxy-2-naphthoate 1,2-dioxygenase EC 1.13.11.39: biphenyl-2,3-diol 1,2-dioxygenase EC 1.13.11.40: arachidonate 8-lipoxygenase EC 1.13.11.41: 2,4′-dihydroxyacetophenone dioxygenase EC 1.13.11.42: identical to EC 1.13.11.11, tryptophan 2,3-dioxygenase EC 1.13.11.43: lignostilbene αβ-dioxygenase EC 1.13.11.44: Activity is covered by EC 1.13.11.60, linoleate 8R-lipoxygenase and EC 5.4.4.6, 9,12-octadecadienoate 8-hydroperoxide 8S-isomerase EC 1.13.11.45: linoleate 11-lipoxygenase EC 1.13.11.46: 4-hydroxymandelate synthase EC 1.13.11.47: 3-hydroxy-4-oxoquinoline 2,4-dioxygenase EC 1.13.11.48: 3-hydroxy-2-methyl-quinolin-4-one 2,4-dioxygenase EC 1.13.11.49: chlorite O2-lyase EC 1.13.11.50: acetylacetone-cleaving enzyme EC 1.13.11.51: 9-cis-epoxycarotenoid dioxygenase EC 1.13.11.52: indoleamine 2,3-dioxygenase EC 1.13.11.53: acireductone dioxygenase (Ni2+-requiring) EC 1.13.11.54: acireductone dioxygenase [iron(II)-requiring] EC 1.13.11.55: sulfur oxygenase/reductase EC 1.13.11.56: 1,2-dihydroxynaphthalene dioxygenase EC 1.13.11.57: gallate dioxygenase EC 1.13.11.58: linoleate 9S-lipoxygenase EC 1.13.11.59: torulene dioxygenase EC 1.13.11.60: inoleate 8R-lipoxygenase EC 1.13.11.61: linolenate 9R-lipoxygenase EC 1.13.11.62: linoleate 10R-lipoxygenase EC 1.13.11.63: β-carotene 15,15′-dioxygenase EC 1.13.11.64: 5-nitrosalicylate dioxygenase EC 1.13.11.65: carotenoid isomerooxygenase EC 1.13.11.66: hydroquinone 1,2-dioxygenase EC 1.13.11.67: 8′-apo-β-carotenoid 14′,13′-cleaving dioxygenase EC 1.13.11.68: 9-cis-β-carotene 9′,10′-cleaving dioxygenase EC 1.13.11.69: carlactone synthase EC 1.13.11.70: all-trans-10′-apo-β-carotenal 13,14-cleaving dioxygenase EC 1.13.11.71: carotenoid-9′,10′-cleaving dioxygenase EC 1.13.11.72: 2-hydroxyethylphosphonate dioxygenase EC 1.13.11.73: methylphosphonate synthase EC 1.13.11.74: 2-aminophenol 1,6-dioxygenase EC 1.13.11.75: all-trans-8′-apo-β-carotenal 15,15′-oxygenase EC 1.13.11.76: 2-amino-5-chlorophenol 1,6-dioxygenase EC 1.13.11.77: oleate 10S-lipoxygenase EC 1.13.11.78: 2-amino-1-hydroxyethylphosphonate dioxygenase (glycine-forming) EC 1.13.11.79: aerobic 5,6-dimethylbenzimidazole synthase EC 1.13.11.80: (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase EC 1.13.11.81: 7,8-dihydroneopterin oxygenase EC 1.13.11.82: 8′-apo-carotenoid 13,14-cleaving dioxygenase EC 1.13.11.83: 4-hydroxy-3-prenylphenylpyruvate oxygenase EC 1.13.11.84: crocetin dialdehyde synthase EC 1.13.11.85: exo-cleaving rubber dioxygenase EC 1.13.11.86: 5-aminosalicylate 1,2-dioxygenase EC 1.13.11.87: endo-cleaving rubber dioxygenase EC 1.13.11.88: isoeugenol monooxygenase EC 1.13.11.89: (hydroxymethyl)phosphonate dioxygenase EC 1.13.11.90: [1-hydroxy-2-(trimethylamino)ethyl]phosphonate dioxygenase (glycine-betaine-forming) EC 1.13.11.91: 3-mercaptopropionate dioxygenase EC 1.13.11.92: fatty acid α-dioxygenase
Sources: en.wikipedia.org
Colomycin 1,000,000 units is 80 mg colistimethate; Coly-mycin M 150 mg colistin base is 360 mg colistimethate or 4,500,000 units. Because colistin was introduced into clinical practice over 50 years ago, it was never subject to the regulations that modern drugs are subject to, and therefore there is no standardised dosing of colistin and no detailed trials on pharmacology or pharmacokinetics. The optimal dosing of colistin for most infections is therefore unknown. Colomycin has a recommended intravenous dose of 1 to 2 million units three times daily for patients weighing 60 kg or more with normal renal function. Coly-Mycin has a recommended dose of 2.5 to 5 mg/kg colistin base a day, which is equivalent to 6 to 12 mg/kg colistimethate sodium per day. For a 60 kg man, therefore, the recommended dose for Colomycin is 240 to 480 mg of colistimethate sodium, yet the recommended dose for Coly-Mycin is 360 to 720 mg of colistimethate sodium. Likewise, the recommended "maximum" dose for each preparation is different (480 mg for Colomycin and 720 mg for Coly-Mycin). Each country has different generic preparations of colistin, and the recommended dose depends on the manufacturer. This complete absence of any regulation or standardisation of dose makes intravenous colistin dosing difficult for the physician. Colistin has been used in combination with rifampicin; evidence of in vitro synergy exists, and the combination has been used successfully in patients.
==== Skin and chronic wounds ==== Dermal regeneration involves the development of bioengineered skin substitutes and advanced wound dressings to treat deep third-degree burns, diabetic foot ulcers, and extensive chronic wounds. Unlike traditional occlusive dressings, regenerative skin scaffolds provide a temporary, porous extracellular matrix analog that coordinates cellular ingress, granulation tissue formation, and re-epithelialization. Commercially available matrices utilize decellularized human or bovine dermal matrices, synthetic biodegradable polymers (such as polycaprolactone), and naturally derived marine biomaterials, including acellular fish skin graphics rich in omega-3 fatty acids. These matrices are designed to modulate the localized inflammatory response, suppress bacterial colonization, and recruit host fibroblasts and keratinocytes to restore functional, vascularized skin tissue while minimizing scar formation.
=== Brand names === Estradiol cypionate has been marketed under the brand names Cicloestradiolo, D-Est, depGynogen, Depo-Estradiol, Depoestra, Depofemin, Depogen, Dura-Estrin, E-Cypionate, E-Ionate, Estradep, Estro-Cyp, Estrofem, Estroject, Estromed-PA, Estronol, Femovirin, Neoginon Depositum, Oestradiol-Retard, Pertradiol, Spendepiol, and T-E Cypionate, among others.
The American Society for Quality (ASQ), formerly the American Society for Quality Control (ASQC), is a society of quality professionals, with more than 30,000 members, in more than 140 countries. ASQC was established on 16 February 1946 by 253 members in Milwaukee, Wisconsin, with George D. Edwards as its first president. The organization was first created as a way for quality experts and manufacturers to sustain quality-improvement techniques used during World War II. In 1948, ASQC's Code of Ethics established standards for members to conduct their activities and business. Business writer Armand V. Feigenbaum served as president of the society in 1961–63. In 1997, the members of the organization voted to change its name from "American Society for Quality Control" to "American Society for Quality".
Sources: en.wikipedia.org
=== Paleoclimate === 12C and 13C are measured as the isotope ratio δ13C in benthic foraminifera and used as a proxy for nutrient cycling and the temperature dependent air–sea exchange of CO2 (ocean ventilation). Photosynthetic organisms, such as algae and plants find it easier to use the lighter carbon isotope (12C) when they convert carbon dioxide and water into glucose and oxygen using sunlight and photosynthesis:
An international study, using modelling and literature assessment, codifies, integrates into and quantifies "safe and just Earth system boundaries" (ESBs) with the context of Earth system stability and minimization of human harm. They expand upon earlier boundary frameworks by incorporating concepts such as intra- and intergenerational justice, propose that their framework may better enable a quantitative foundation for safeguarding the global commons, and report many of the ESBs are already exceeded. Healthcare systems related results are published: large increases in medication prices via sustained decrease in their use can cause poorer disease control (8 May), widespread implementation of the particular Alzheimer's disease therapeutic solution lecanemab may increase annual U.S. Medicare spending by $2.0 to $5.1 billion (11 May), mailed HPV self-collection kits with scheduling assistance can lead to greater uptake of cervical cancer screening (11 May), cost-related medication nonadherence occurs in approximately 1 in 5 older adults in the U.S. in 2022 (18 May), and a QALY-based health economics study evaluates the cost-effectiveness of U.S. population-wide screening for CKD (23 May).
This list of sequenced animal genomes contains animal species for which complete genome sequences have been assembled, annotated and published. Substantially complete draft genomes are included, but not partial genome sequences or organelle-only sequences. For all kingdoms, see the list of sequenced genomes.
Chapter 1: Continuous Population Models for Single Species Chapter 2: Discrete Population Models for a Single Species Chapter 3: Models for Interacting Populations Chapter 4: Temperature-Dependent Sex Determination (TSD) Chapter 5: Modelling the Dynamics of Marital Interaction: Divorce Prediction and Marriage Repair Chapter 6: Reaction Kinetics Chapter 7: Biological Oscillators and Switches Chapter 8: BZ Oscillating Reactions Chapter 9: Perturbed and Coupled Oscillators and Black Holes Chapter 10: Dynamics of Infectious Diseases Chapter 11: Reaction Diffusion, Chemotaxis, and Nonlocal Mechanisms Chapter 12: Oscillator-Generated Wave Phenomena Chapter 13: Biological Waves: Single-Species Models Chapter 14: Use and Abuse of Fractals
The talks came close to achieving an overall breakthrough on nuclear arms control, but ended in failure due to Reagan's proposed Strategic Defense Initiative and Gorbachev's proposed cancellation of it. Like Reagan, British Prime Minister Margaret Thatcher also got along well with Gorbachev despite her pronounced anticommunism; she was subsequently encouraged by both his optimistic domestic reform agenda and his arms-control efforts through the mid-1980s. Fundamental to the dissolution of the Soviet Union, the Gorbachev policy initiatives of "restructuring" (perestroika) and "openness" (glasnost) had broad ramifications. To this end, historian Sheila Fitzpatrick wrote of glasnost:
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.